People · Operator
Named in public records as an officer, director or promoter · active 2017–2023 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Eumentis Therapeutics, Inc. | — | Pharmaceuticals | Series A | $11.3M | $36.8M | 2018 |
| ArTara Therapeutics, Inc. | — | Pharmaceuticals | Series A | $4.2M | $128.5M | 2017 |
Randall Marshall at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Randall Marshall on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Smith | 1 | 42 |
| Mark Tepper | 1 | 3 |
| James Larrick | 1 | 2 |
| Andrew Pearlman | 1 | 2 |
| Maryann Bryla | 1 | 1 |
| Kim Patrick | 1 | 1 |
| Amar Kapur | 1 | 1 |
| Jesse Shefferman | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.